The addition of tricuspid transcatheter edge-to-edge repair to optimal medical therapy using the PASCAL device produced greater reductions in tricuspid regurgitation (TR), reduced the need for future interventions, and resulted in a more substantial improvement in quality of life than medical therapy alone, according to the CLASP II TR trial. Findings were presented Monday November 1, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego.